Trials / Completed
CompletedNCT01630733
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 664 (actual)
- Sponsor
- Achieve Life Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to compare overall survival of participants randomized to receiving custirsen in combination with docetaxel with participants randomized to receive docetaxel alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Custirsen | |
| DRUG | Docetaxel |
Timeline
- Start date
- 2012-10-24
- Primary completion
- 2016-11-17
- Completion
- 2016-11-17
- First posted
- 2012-06-28
- Last updated
- 2026-04-15
Locations
78 sites across 14 countries: United States, Australia, Germany, Hungary, Israel, Italy, New Zealand, Poland, Russia, South Korea, Spain, Taiwan, Thailand, Ukraine
Source: ClinicalTrials.gov record NCT01630733. Inclusion in this directory is not an endorsement.